Spcs in the Netherlands 2026: Granting, Term, Enforcement and UPC Risk for Chemical & Biotech Patentees

Supplementary protection certificate netherlands strategy has become a board-level concern for chemical and biotech patentees in 2026, as elevated Unified Patent Court (UPC) activity and evolving European Union case law reshape how term, scope and enforcement play out. A supplementary protection certificate (SPC) extends patent-like protection for medicinal and plant protection products beyond the standard 20-year patent term, compensating rights holders for the years lost to regulatory approval. For companies with high-value active ingredients, the difference between a well-timed SPC filing and a missed deadline can represent substantial market exclusivity. This practical guide sets out eligibility, filing procedure, worked term calculations, scope limits, validity risks and the forum choice between Dutch national courts and the UPC.

Throughout, the emphasis is on decisions that in-house counsel, IP managers and R&D heads must make now.

Executive summary: what Dutch chemical & biotech patentees must know in 2026

TL;DR: Check your first marketing authorisation (MA) date, compute the term precisely, and assess forum risk between the UPC and Dutch courts before you enforce. These three actions govern almost every SPC decision.

The core rules for medicinal products flow from Regulation (EC) No 469/2009; plant protection products are governed by the parallel Regulation (EC) No 1610/96. An SPC is available where a valid basic patent protects a product that has received a marketing authorisation as a medicinal or plant protection product. The following points capture the essentials for 2026:

• Time to file. An SPC application must be lodged within six months of the grant of the marketing authorisation (or within six months of patent grant, where the patent is granted after the MA).
• Term formula. The SPC duration equals the period between the basic patent filing date and the date of the first MA in the European Economic Area (EEA), minus five years, capped at a maximum of five years.
• Paediatric extension. A further six months may be added where the requirements of the Paediatric Regulation (EC) No 1901/2006 are met, including completion of an agreed paediatric investigation plan.
• UPC risk. SPCs based on European patents may be litigated before the UPC, changing the calculus on cross-border relief, revocation exposure and injunction prospects.
• Manufacturing waiver. A limited exception introduced by Regulation (EU) 2019/933 permits third parties to manufacture for export or stockpiling, subject to strict notification and labelling compliance.

For chemical and biotech portfolios, the technical characterisation of the “product”, a single active substance, a salt or ester, a combination, or a second medical use, determines both eligibility and term. Getting that characterisation right is the single most important step in any supplementary protection certificate netherlands assessment.

What is an SPC and eligibility in the Netherlands

An SPC is a sui generis intellectual property right created by Regulation (EC) No 469/2009 for medicinal products and by Regulation (EC) No 1610/96 for plant protection products. It is not a patent, but it confers, during its term, the same rights and is subject to the same limitations as the basic patent from which it derives. The purpose is straightforward: to restore a portion of the effective patent term consumed by the regulatory approval process, which for pharmaceuticals and agrochemicals can run to a decade or more.

To obtain a supplementary protection certificate in the Netherlands, four conditions in Article 3 of the Regulation must be satisfied at the date of application. The product must be protected by a basic patent in force; a valid marketing authorisation to place the product on the market as a medicinal product must have been granted; the product must not already have been the subject of an SPC; and the authorisation relied upon must be the first authorisation to place the product on the market as a medicinal product. Each of these conditions has generated substantial CJEU case law, particularly around what it means for a product to be “protected by” the basic patent.

SPC statutory basis and how national offices apply the Regulation

The SPC is an EU-wide instrument, but it is granted, administered and litigated at national level. In the Netherlands, applications are examined by the Netherlands Patent Office (Octrooicentrum Nederland, part of RVO), which applies Regulation (EC) No 469/2009 directly. There is no separate Dutch “SPC statute”, the Regulation is directly effective, with the Dutch Patents Act (Rijksoctrooiwet 1995) providing procedural context. National offices assess formal requirements and the Article 3 conditions, but questions of interpretation are ultimately harmonised through the Court of Justice of the European Union. This means a Dutch grant decision can turn on a CJEU ruling handed down in a reference from another Member State, reinforcing the need to track European case law closely.

What counts as a “product” (active substance, esters, salts, combinations), implications for chemicals & biologics

The definition of “product” is the fulcrum of SPC practice. Under the Regulation, a “product” means the active ingredient or combination of active ingredients of a medicinal product. This definition has significant consequences for chemical and biotech patentees.

• Single active substances. A small-molecule active ingredient is generally the cleanest case, provided the basic patent claims it specifically.
• Salts, esters and derivatives. A different salt or ester of the same therapeutic moiety may or may not qualify as a distinct “product,” depending on how the claims and the authorisation align. This is a recurring area of dispute for chemical entities.
• Combinations. A combination of active ingredients can support an SPC, but only where the combination as such is protected by the basic patent and authorised as a product.
• Biologics. For biotech products, the “active substance” may be an antibody, a fusion protein or a recombinant molecule, and questions arise around functional definitions, glycosylation variants and the boundary between the claimed molecule and the authorised product.

For biologics in particular, aligning the basic patent claims with the EMA-authorised product is a technical exercise best undertaken at the drafting stage, long before the supplementary protection certificate netherlands application is contemplated.

SPC filing procedure in the Netherlands, timeline and practical checklist

The procedure is document-driven and deadline-critical. Because the six-month window is a hard limit, filing preparation should begin as soon as a marketing authorisation is on the horizon. A missed deadline generally cannot be cured, and the value of years of exclusivity can be lost through a purely administrative oversight.

The sequence typically runs as follows: identify the basic patent and confirm it is in force; confirm the first EEA marketing authorisation and its exact grant date; verify that the product falls within the scope of the basic patent; assemble the required documents; and lodge the application with the national authority within the prescribed period, paying the applicable fees as set by the Netherlands Patent Office. Where a company holds parallel patents and authorisations across Europe, the sequencing of national SPC filings should be coordinated to avoid inconsistent product definitions and to preserve enforcement options.

Required documents and declarations

A complete SPC application in the Netherlands generally requires the application form identifying the applicant and the basic patent; a copy of the marketing authorisation together with the summary of product characteristics; the date and place of the first authorisation in the EEA where the Dutch MA is not the first; and details enabling the authority to identify the product. The declaration of the first EEA marketing authorisation is critical because it drives the term calculation. An error in the declared MA date can shorten or invalidate the certificate, so this figure should be verified against the authorisation itself and, where relevant, against EMA records.

Filing calendar and practical checklist

• Patent expiry date. Record the 20-year expiry of each basic patent and diarise it years in advance.
• MA grant date. Capture the exact date of the first EEA authorisation as soon as it issues.
• Six-month window. Diarise the SPC filing deadline immediately, six months from the MA grant (or patent grant, if later).
• Internal alerts. Notify procurement, regulatory affairs and manufacturing so that supply-chain planning aligns with the anticipated extended term.
• Cross-EU coordination. Map parallel filings so that product definitions and term calculations are consistent across jurisdictions.

SPC term calculation, formula, worked examples and pitfalls

Term calculation is where most value is won or lost, and where errors are most costly. The formula in Regulation (EC) No 469/2009 is deceptively simple, but its application to combinations, biologics and second medical use products requires care.

Basic formula and statutory caps

The duration of an SPC equals the period elapsed between the date on which the application for the basic patent was lodged and the date of the first authorisation to place the product on the market in the EEA, reduced by five years. The resulting term cannot exceed five years. In practice, this means an SPC delivers value only where more than five years elapsed between patent filing and first EEA authorisation; where the gap is precisely five years, the term is zero, and where it exceeds ten years, the term is capped at five.

Where the requirements of the Paediatric Regulation are met, a further six months can be added, taking the maximum effective extension to five and a half years.

Worked example, small molecule chemical product

Consider a small-molecule chemical entity. The basic patent was filed on 1 March 2008. The first EEA marketing authorisation was granted on 1 September 2020. The interval between patent filing and first MA is twelve years and six months. Subtracting five years gives seven years and six months. Because the statutory cap is five years, the SPC term is limited to five years, commencing on expiry of the basic patent (1 March 2028) and running to 1 March 2033. This is the classic scenario in which the cap bites and the full theoretical restoration is not achieved.

Worked example, biologic / biotech product

Now consider a biologic. The basic patent was filed on 1 June 2012. The first EEA authorisation, granted through the centralised EMA procedure, issued on 1 December 2020. The interval is eight years and six months. Subtracting five years yields an SPC term of three years and six months. The certificate therefore takes effect on expiry of the patent (1 June 2032) and runs to 1 December 2035. If the paediatric extension applies, six months may be added, extending protection to 1 June 2036. For biologics, confirming the precise centralised authorisation date is essential, since the centralised procedure fixes a single EEA-wide date.

Worked example, combination and second medical use

Combination products and second medical use cases require the practitioner to identify the correct “product” and the correct “first authorisation” for that product. Suppose a combination of two active ingredients is protected by a basic patent filed on 1 January 2010, and the combination product receives its first EEA authorisation on 1 January 2019. The interval is nine years, giving an SPC term of four years. However, if one of the individual actives had earlier been authorised alone, careful analysis is needed to determine whether the combination qualifies as a distinct product and whether the relied-upon authorisation is genuinely the first for that combination.

Second medical use scenarios raise analogous questions: the authorisation for a new therapeutic indication may or may not support a fresh SPC, depending on how the product and the basic patent claim interact. These are precisely the areas where a supplementary protection certificate netherlands assessment benefits from technical and legal review in tandem.

The most common pitfalls are: using the Dutch MA date instead of the first EEA date; overlooking an earlier authorisation of the same active elsewhere in the EEA; and misclassifying a salt or combination. Each of these can shorten or invalidate the term.

SPC scope of protection and manufacturing waiver, what Dutch manufacturers need to know

The scope of an SPC is defined by reference to the basic patent, but confined to the product covered by the authorisation and to any use of the product as a medicinal product authorised before expiry of the certificate. This is narrower than the full scope of the basic patent: the SPC protects the authorised product, not every embodiment the patent might otherwise reach. Understanding this boundary is essential both for enforcement and for freedom-to-operate analysis.

When can a third party manufacture or export?

Regulation (EU) 2019/933 introduced a manufacturing waiver to the SPC regime that allows, under defined conditions, the making of a protected product (or a medicinal product containing it) for the purpose of export to countries outside the EU, and, during the final six months before SPC expiry, for stockpiling so that generic and biosimilar producers can enter the EU market on day one after expiry. Reliance on the waiver is conditional and not automatic. Manufacturers must comply with notification requirements to the competent national authority and to the SPC holder, apply the prescribed logo and labelling obligations on products intended for export, and observe the specified timing rules.

A Dutch manufacturer intending to rely on the waiver should treat compliance as a formal legal project, not an operational afterthought, because defects in notification or labelling can convert lawful activity into infringement.

Practical compliance checklist for Dutch manufacturers

• Map the relevant SPCs. Identify every SPC affecting the target product across the EEA.
• Confirm waiver eligibility. Verify that the intended activity falls within the export or stockpiling permission and its timing constraints.
• Serve notifications. Notify the competent authority and the SPC holder in the prescribed form and within the prescribed period.
• Apply labelling. Ensure export products carry the required EU export logo and identifiers.
• Document everything. Retain records evidencing compliance in case the SPC holder challenges the activity.

Validity, opposition and common attack vectors in the Netherlands

SPCs are frequently attacked, and a defensible SPC is one whose product definition, basic patent and authorisation all align. Because an SPC is derivative of the basic patent, weaknesses in the patent flow directly into the certificate.

Typical grounds and case law trends

The most common grounds of attack in the Netherlands mirror those seen across the EU. First, invalidity of the basic patent: if the patent is revoked or lapses, the SPC falls with it. Second, lack of conformity between the product and the claims, the challenge that the product is not “protected by” the basic patent within the meaning of Article 3(a), an issue the CJEU has revisited repeatedly. Third, that the relied-upon authorisation was not the first authorisation for the product in the EEA, defeating Article 3(d). Fourth, that the product had already been the subject of an SPC, breaching Article 3(c).

CJEU jurisprudence on Article 3(a), how specifically the product must be identified in the claims, remains among the most litigated questions, and it continues to evolve. Patentees should therefore ensure that the basic patent claims identify the authorised product with sufficient precision, and opponents should scrutinise exactly that alignment.

Procedural route, national revocation actions vs attacks at UPC

An SPC’s validity can be challenged through national proceedings before the Dutch courts, or, where the SPC derives from a European patent within the UPC system, potentially before the Unified Patent Court. The choice of route carries significant strategic weight. National revocation before the Dutch courts produces a decision limited to the Netherlands, contained and predictable but without cross-border reach. A challenge at the UPC, by contrast, can affect the SPC across the participating Member States in a single action, magnifying both the reward for a successful challenger and the exposure for the SPC holder.

Because the UPC’s competence over SPCs is tied to the underlying European patent and any opt-out choices made for that patent, holders must review their opt-out position before assuming they can confine disputes to national fora. A patent that has not been opted out of the UPC exposes any derived SPC to central attack, a fact that should inform portfolio strategy from the outset of any supplementary protection certificate netherlands programme.

Enforcement options, Dutch courts vs the Unified Patent Court in 2026

Enforcement is where strategy meets reality. In 2026, the coexistence of the Dutch national courts and the UPC gives patentees a genuine choice of forum, and that choice materially affects speed, remedies, geographic reach and risk. The Dutch courts are highly experienced in life-sciences patent litigation and offer respected preliminary injunction practice. The UPC offers pan-European relief across participating Member States in a single proceeding but concentrates revocation risk.

Can SPCs be enforced before the UPC? Jurisdictional principles

The UPC’s jurisdiction extends to SPCs granted on the basis of European patents falling within the court’s competence, subject to the transitional regime and any opt-out. Where the underlying European patent has not been opted out, the SPC derived from it can, in principle, be enforced before the UPC, with the potential for injunctive relief spanning the participating Member States in which the SPC is in force. Conversely, if the basic patent has been opted out, enforcement of the derived SPC will generally proceed through national courts, including the Dutch courts. The practical lesson is that forum options for an SPC are largely determined by decisions taken at the patent level, often years earlier.

Patentees should therefore audit the opt-out status of every basic patent underpinning a valuable SPC.

Tactical considerations: injunctions, damages, recall, customs seizures

The remedial toolkit differs in emphasis between the two fora. Both can grant preliminary and permanent injunctions, damages and orders for recall or destruction, but the geographic reach and procedural rhythm differ. A UPC injunction can cover multiple participating markets at once, delivering commercial leverage that a national injunction cannot match, but it also invites a counterclaim for revocation that, if successful, extinguishes protection across the same footprint. Dutch national proceedings offer a more contained battlefield, fast in some preliminary contexts and with a well-developed body of life-sciences jurisprudence. Customs measures and border seizures can complement either route to intercept infringing imports.

The choice between speed, breadth and risk containment should be made case by case, weighing the strength of the SPC, the opt-out position and the commercial geography of the infringement.

Practical litigation checklist for patentees

• Confirm SPC validity and term. Re-verify the product definition, MA date and calculated term before acting.
• Check opt-out status. Determine whether the basic patent is within or outside the UPC.
• Assess revocation exposure. Model the downside if a UPC counterclaim succeeds across multiple markets.
• Map the infringement geography. Match the forum to where the commercial harm is concentrated.
• Preserve evidence. Secure product samples, supply-chain data and market evidence early.

Practical risk-management checklist for chemical & biotech patentees

Effective SPC management is proactive, not reactive. The following actionable checklist consolidates the recurring decisions for chemical and biotech portfolios:

• Filing reminders. Diarise every six-month SPC deadline and every basic patent expiry across the portfolio.
• Product-definition discipline. Align basic patent claims with the authorised product at the drafting stage, especially for salts, combinations and biologics.
• Term verification. Independently confirm the first EEA MA date and re-run the term calculation before filing and before enforcing.
• Opt-out audit. Record the UPC opt-out status of every basic patent to preserve or shape enforcement options.
• Supply-chain instructions. Brief manufacturing and procurement on extended terms and on manufacturing-waiver compliance obligations.
• Competitor monitoring. Watch for biosimilar and generic filings and for waiver notifications served on the SPC holder.
• Pre-litigation readiness. Prepare evidence preservation protocols and outline the forum-choice analysis in advance.
• Regulatory exclusivity coordination. Combine SPC protection with data and market exclusivity strategies for maximum effective coverage.

Next steps and how we can help

A fast, reliable supplementary protection certificate netherlands assessment starts with a small set of core inputs: the basic patent number, the first EEA marketing authorisation date, a precise product definition, the intended or actual manufacturing sites, and the UPC opt-out status of the patent. With these, it is possible to confirm eligibility, calculate the term and model the enforcement and revocation risk across the Dutch courts and the UPC. Early advice is disproportionately valuable, because the most consequential decisions, claim drafting, filing timing and opt-out strategy, must be taken well before any dispute arises.

Explore our Intellectual Property practice, Netherlands and the Netherlands, IP lawyer directory (filter: Intellectual Property) to identify the right specialist for a jurisdictional assessment and case-specific enforcement strategy.

Sources

1. Regulation (EC) No 469/2009 (SPC Regulation for medicinal products), EUR-Lex
2. Regulation (EC) No 1610/96 (SPC Regulation for plant protection products), EUR-Lex
3. Regulation (EU) 2019/933 (SPC manufacturing waiver), EUR-Lex
4. CURIA, Court of Justice of the European Union case law portal
5. Unified Patent Court, official site
6. European Medicines Agency (EMA)
7. Netherlands Enterprise Agency (RVO) / Netherlands Patent Office